Composition for diagnosing pancreatic cancer and method for diagnosing pancreatic cancer using the same
The present invention relates to: a composition for diagnosing pancreatic cancer, containing a preparation for measuring the expression level of a protein or a gene thereof, and capable of being used for determining whether there is a risk of pancreatic cancer; a kit; and a method for diagnosing pancreatic cancer by using the same. The present invention can significantly predict or identify the risk of pancreatic cancer or a precancerous lesion of pancreatic cancer, the early diagnosis thereof and the extent of diseases thereof by providing a diagnostic marker of pancreatic cancer, and can be utilized in the research of pancreatic cancer oncogenesis. In addition, the diagnostic method of the present invention can provide simple and early diagnosis of pancreatic cancer from the blood and the like in a non-invasive manner.
1. A method for detecting the expression of proteins in a subject suspected of having pancreatic cancer, comprising:
obtaining a sample from a subject suspected of having pancreatic cancer,
measuring a protein expression level of at least three proteins from the sample suspected of having pancreatic cancer,
comparing the expression level of the at least three proteins between the sample from the subject suspected of having pancreatic cancer and a sample from a normal group,
wherein the at least three proteins comprise (a) CA19-9 (carbohydrate antigen 19-9), (b) LRG1 (Leucine-rich alpha-2-glycoprotein 1, LRG), and (c) at least one selected from the group consisting of TTR (Transthyretin, ATTR, Prealbumin, TBPA), C1R (Complement C1r subcomponent precursor), CLU (Clusterin preproprotein), and KLKB1 (Plasma Kallikrein protein).
2. The method of claim 1 , wherein
expression levels of both (a) CA19-9 and (b) LRG1 are higher in the subject suspected of having pancreatic cancer than in the normal control; and an expression level of any one of (c) at least one of TTR, CLU and KLKB1 is lower in the subject suspected of having pancreatic cancer than in the normal control, or an expression level of C1R is higher the subject suspected of having pancreatic cancer than in the normal control.
3. The method of claim 1 , wherein a calculation is performed using
f
(
x
)
=
sgn
(
∑
i
=
1
n
α
i
y
i
〈
x
,
x
i
〉
+
b
)
Formula
1
wherein, x is an expression level measurement of one of the proteins,
α i is a Lagrange multiplier in SVM,
γ i is a separator of normal group/pancreatic cancer group,
x i is a reference measurement, and
b is a correction value.
4. The method of claim 1 , wherein the sample is blood, serum or plasma.
5. The method of claim 1 , wherein the measuring of protein expression level utilizes antibodies, oligopeptides, ligands, PNAs (peptide nucleic acids), or aptamers that can specifically bind to corresponding protein, respectively.
6. The method of claim 1 , wherein the pancreatic cancer has a possibility of being pancreatic ductal adrenocarcinoma (PDAC).
7. The method of claim 6 , wherein the pancreatic ductal adrenocarcinoma is IPMN-derived pancreatic ductal adenocarcinoma.
8. The method of claim 1 , wherein the subject suspected of having pancreatic cancer has a CA19-9 of less than 37 U/ml.
9. The method of claim 1 , wherein the pancreatic cancer is pancreatic ductal adenocarcinoma or high-risk intraductal papillary mucinous neoplasm (IPMN).